The serotonin paradox: Negative symptoms and SSRI augmentation

International Journal of Psychiatry in Clinical Practice

Volumn 2, Issue 1, 1998, Pages 19-26

  Zullino, Daniele ^a   Bondolfi, Guido ^a   Baumann, Pierre ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

Antipsychotics; Combination treatment; Negative symptoms; Schizophrenia; Selective serotonin re uptake inhibitors

Indexed keywords

CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ANHEDONIA; DRUG EFFECT; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME;

EID: 0031981323     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.3109/13651509809115109     Document Type: Review

References (65)

1. World Health Organisation (1995) World Health Report 1995. WHO, Geneva.
2. Kane JM (1996) Factors which can make patients difficult to treat. Br J Psychiatry 169(Suppl. 31): 10-14.
3. Kane J, Honigfeld G, Singer J et al (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789-96.
4. Krupp P, Barnes P (1989) Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 99: 118-21.
5. Amsler HA, Teerenhovi L, Barth E et al (1977) Agranulocytosis in patients treated with clozapine - A study of the Finnish epidemic. Acta Psychiatr Scand 56: 241-8.
6. Gaebel W, Wōlwer W (1994) Probleme der Abgrenzung von Depression, Akinesie und Minussymptomatik mittels Beurteilungsskalen und Verhaltensbeobachtung: Messmethodisches Artefakt oder Ausdruck pathogenetischer Identitāt? In: Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik, (eds HJ Mōller and G Laux) 27-38. Springer-Verlag, Wien.
7. Newcomer JW, Faustman WO, Yeh W et al (1990) Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. Psychol Rep 31: 243-50.
8. Plasky P (1991) Antidepressant usage in schizophrenia. Schizophr Bull 17: 649-57.
9. Siris SG (1993) Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 163: 66-78.
10. Evans AE, Goff DC (1996) Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drugs 6: 130-47.
11. Siris S, Bermanzohn PC, Gonzales A et al (1991) The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull 27: 331-5.
12. Boyer WF, Feighner JP (1996) Safety and tolerability of selective serotonin re-uptake inhibitors. In: Selective serotonin re-uptake inhibitors (eds JP Feighner and WF Boyer) J Wiley, Chichester.
13. Iqbal N, van Praag M (1995) The role of serotonin in schizophrenia. Eur Neuropsychopharmacol (Suppl. 5) 11-23.
14. Meltzer HY (1992) The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 160: 22-9.
15. Richelson E (1996) Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 57: 4-11.
16. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825-35.
17. Carman J, Peuskens J, Vangeneugen A (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a metaanalysis. Int Clin Psychopharmacol 10: 207-13.
18. Rossi A, Mancini F, Stratta P et al (1997) Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 95: 40-3.
19. Azorin JM (1995) Long-term treatment of mood disorders in schizophrenia. Acta Psychiatr Scand 91: 20-3.
20. Fleischhacker WW (1995) New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand 91: 24-30.
21. Smith RC, Chua JW, Lipetsker B et al (1996) Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: An open prospective study. J Clin Psychiatry 57: 460-66.
22. Borison RL (1995) Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 15: 24S-29S.
23. Hillert A, Maier W, Wetzel H et al (1992) Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome - A functional approach. Pharmacopsychiatry 25: 213-7.
24. Hamon M (1995) Sérotonine/5-hydroxytryptamine (5-HT). In: Neuropeptides et neuromédiateurs (ed. J Epelbaum), pp. 261-70. Inserm, Paris.
25. Silver H, Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double-blind, placebo-controlled study. Biol Psychiatry 31: 698-704.
26. Spina E, De Domenico P, Ruello C et al (1994) Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 9: 281-5.
27. Goff DC, Midha KK, Sarid-Segal O et al (1995) A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 117: 417-23.
28. Vartiainen H, Tiihonen J, Putkonen A et al (1995) Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 91: 348-51.
29. Salokangas RKR, Saarijärvi S, Taiminen T et al (1996) Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 94: 175-80.
30. Taiminen T, Syvālathi E, Saarijārvi S et al (1997) Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int Clin Psychophannacol 12: 31-5.
31. Goff DC, Brotman AW, Waites M et al (1990) Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 147: 492-4.
32. Syvälathi EKG, Kallioniemi H, Lehto H (1994) Citalopram in patients with unsatisfactory response to neuroleptics: An open follow-up study. Meth Find Exp Clin Pharmacol 16: 49-55.
33. Silver H, Kaplan A, Kushnir M (1995) Fluvoxamine augmentation in chronic schizophrenia: An open exploratory study. Hum Psychopharmacol 10: 59-63.
34. Bacher NM, Ruskin P (1991) Addition of fluoxetine to treatment of schizophrenic patients. Am j Psychiatry 148: 274-5.
35. Thakore JH, Berti C, Dinan TG (1996) An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiatr Scand 94: 194-7.
36. Baldessarini RJ, Frankenburg FR (1991) Clozapine. A novel antipsychotic agent. N Engl J Med 324: 746-54.
37. Barnes TRE, McEvedy CJB, Nelson HE (1996) Management of treatment resistant schizophrenia unresponsive to clozapine. Br J Psychiatry 169: 31-40.
38. Buchanan RW, Kirkpatrick B, Bryant N et al (1996) Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 153: 1625-7.
39. Silver H, Kaplan A, Jahjah N (1995) Fluvoxamine augmentation for clozapine-resistant schizophrenia. Am J Psychiatry 152: 1098.
40. Silver H, Kushnir M, Kaplan A (1996) Fluvoxamine augmentation in clozapine-resistant schizophrenia: An open pilot study. Biol Psychiatry 40: 671-4.
41. Arndt S, Andreasen NC, Flaum M et al (1995) A longitudinal study of symptoms dimensions in schizophrenia. Arch Gen Psychiatry 52: 352-60.
42. Salokagas RKR (1997) Structure of schizophrenic symptomatology and its changes over time: Prospective factor-analytical study. Acta Psychiatr Scand 95: 32-9.
43. Carpenter WT (1995) Serotonin-dopamine antagonists and treatment of negative symptoms. J Clin Psychopharmacol 15: 30S-35S.
44. Czobon P, Volavka J (1996) Positive and negative symptoms: Is their change related? Schizophr Bull 22: 577-90.
45. Tollefson GD, Sanger TM (1997) Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466-74.
46. Lipinski JF, Mallya G, Zimmermann P et al (1989) Fluoxetine-induced akathisia: Clinical and theoretical implications. J Clin Psychiatry 50: 339-42.
47. Bouchard RH, Pourcher E, Vincent P (1989) Fluoxetine and extrapyramidal side effects. Am J Psychiatry 146: 1352-3.
48. Halman M, Goldbloom DS (1990) Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 28: 518-21.
49. Leo RJ (1996) Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57: 449-54.
50. Hamilton MS, Opler LA (1992) Akathisia, suicidality, and fluoxetine. J Clin Psychiatry 53: 401-6.
51. Sanz-Fuentenebro FJ, Huidobro A, Tejadas-Rivas A (1996) Restless legs syndrome and paroxetine. Acta Psychiatr Scand 94: 482-4.
52. Balant-Gorgia AE, Ries C, Balant LP (1996) Metabolic interaction between fluoxetine and clomipramine: A case report. Pharmacopsychiatry 29: 38-41.
53. Tate JL (1989) Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 146: 399-400.
54. Stein MH (1991) Tardive dyskinesia in a patient taking haloperidol and fluoxetine. Am J Psychiatry 148: 683.
55. Preskorn SH (1996) Clinical pharmacology of selective serotonin reuptake inhibitors. Professional Communications Inc, Caddo, OH, USA.
56. Dubovsky SL, Thomas M (1995) Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 56: 38-48.
57. Meltzer HY, Okaly G (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. Am J Psychiatry 152: 183-90.
58. Tamminga CA, Holcomb HH, Gao WM et al (1995) Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 10: 29-37.
59. Müller-Spahn F, Eich P, Hock C (1996) The psychobiology of the acute schizophrenic episode. Int Clin Psychopharmacol 11: 19-28.
60. Jerling M, Dahl ML, Aberg-Wistedt A (1996) The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. din Pharmacol Ther 59: 423-8.
61. Linnet K, Wiborg O (1996) Influence of CYP2D6 polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 18: 629-34.
62. Haring C, Meise U, Humpel C et al (1989) Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacol 99: S38-S40.
63. Hiemke C, Weigman H, Hārtter S et al (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14: 279-81.
64. Brunette MF, Muesner KT, Haiyi X et al (1997) Relationships between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis 185: 13-20.
65. Llerena A, Kilvet RA (1994) Fixed combinations of neuroleptics with antidepressants: potential risks and estimation of use. Br J Clin Pharmacol 37: 531-2.